Liver Transplant Clinical Trial
Official title:
A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation (ITN073ST)
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
The researchers in this study plan to enroll 9 participants who will receive at least the target Treg product (arTreg-CSB) dose of 2.5 x 10^6 cells. Participants who receive at least 1 x 10^6 cells but < 2.5 x 10^6 cells as a result of low cell yield will be included in intent-to-treat (ITT) analysis. Participants who successfully withdraw from all immunosuppression will undergo a research biopsy at 52 weeks following drug discontinuation to determine whether they meet the primary efficacy outcome of operational tolerance. Participants determined to be operationally tolerant will be followed until 104 weeks following drug discontinuation and have a research biopsy at that time to confirm that they remain operationally tolerant. Participants who fail drug withdrawal after 52 weeks but before 104 weeks will be followed until week 104 or 12 weeks after resuming immunosuppression, whichever is longer. The research biopsy at week 104 will be optional for these participants. Participants who do not successfully withdraw from all immunosuppression will complete 104 weeks of High Intensity Safety Follow-up after failing immunosuppression withdrawal. *** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
| Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
| Completed |
NCT01696331 -
Text Messaging for Adherence in Adolescent Liver Transplant Recipients
|
N/A | |
| Recruiting |
NCT05051605 -
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
|
||
| Recruiting |
NCT05940857 -
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
|
||
| Completed |
NCT01598987 -
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
|
Phase 3 | |
| Active, not recruiting |
NCT05074160 -
OCS Liver Perfusion (OLP) Post-Approval Registry
|
||
| Completed |
NCT05087550 -
Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
|
||
| Recruiting |
NCT04836923 -
LIFT Intervention in Liver Transplant Candidates
|
N/A | |
| Not yet recruiting |
NCT03666689 -
Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
|
||
| Not yet recruiting |
NCT06088758 -
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
|
N/A | |
| Terminated |
NCT01230502 -
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
|
N/A | |
| Completed |
NCT00171509 -
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
|
Phase 4 | |
| Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06075745 -
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
|
Phase 2 | |
| Completed |
NCT02057484 -
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
|
||
| Recruiting |
NCT06342557 -
Transitional ePRO Diary Liver
|
||
| Not yet recruiting |
NCT04265157 -
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
|
||
| Recruiting |
NCT02863250 -
Australian and New Zealand Massive Transfusion Registry
|
||
| Completed |
NCT00698399 -
Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients
|
N/A |